News
4d
Pharmaceutical Technology on MSNMSD’s Gardasil sales slide further due to China constraintsMSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.
On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...
Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...
The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...
10h
Zacks.com on MSNShould You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.
Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...
GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.
SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.
1436 GMT – Merck’s struggles with Gardasil aren’t easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to ...
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results